Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

By LabMedica International staff writers
Posted on 01 Mar 2015
Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis.

E. More...
faecalis, a bacterium inhabiting the gastrointestinal tracts of humans, is an important pathogen found in many infections including endocarditis, urinary tract infection, meningitis, and persistent infections associated with root canal treatment failure. The difficulty in E. faecalis treatment has been attributed to the lack of anti-infective strategies to eradicate its biofilm and to the frequent emergence of multidrug resistant strains.

Investigators at the Hebrew University of Jerusalem (Israel) evaluated the possibility of treating E. faecalis infections with specific bacteriophages, viruses that infect and destroy bacteria. To this end, they isolated an anti-E. faecalis and E. faecium phage, from effluents obtained from a Jerusalem (Israel), sewage treatment facility.

The EFDG1phage was visualized by electron microscopy. EFDG1 DNA coding sequences and phylogeny were determined by whole genome sequencing, which revealed that it belonged to the Spounavirinae subfamily of the Myoviridae phages, which includes promising candidates for therapy against Gram positive pathogens. This analysis also showed that the EFDG1 genome did not contain apparent harmful genes.

EFDG1 antibacterial efficacy was evaluated in vitro against planktonic and biofilm cultures. Results published in the February 6, 2015, online edition of the journal Applied and Environmental Microbiology showed that the phage displayed effective lytic activity against various E. faecalis and E. faecium isolates, regardless of their antibiotic resistance profile. Additionally, EFDG1 efficiently prevented ex vivo E. faecalis root canal infection.

Senior author Dr. Ronen Hazan, professor of dental sciences at the Hebrew University of Jerusalem, said, “The idea of using phages as antibacterial drugs is not new. Phage therapy was first proposed at the start of the 20th century, but then abandoned for various reasons, including the striking success of chemical antibiotics. Now we stand on the verge of a new era with the limitations of synthetic antibiotics and the emergence of antibiotic-resistant strains of bacteria. Thus it is the right time to look again into what Mother Nature offers in the battle against bacteria. As this research shows, bacteriophages may prove an effective tool in the development of much-needed new antimicrobial drugs.”

Hebrew University of Jerusalem

Related Links:

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
All-in-One Molecular System
AIO M160
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.